NCT03572231View on ClinicalTrials.gov

A Registry Study of Patients Initiating a Course of Drug Therapy for Overactive Bladder in Taiwan, Korea and China

CompletedOBSERVATIONAL

Enrollment

805

Participants

Timeline

Start Date

July 19, 2018

Primary Completion Date

March 30, 2020

Study Completion Date

March 30, 2020

Conditions

Overactive Bladder (OAB)

Interventions

DRUG

mirabegron

oral

DEVICE

solifenacin

oral

DRUG

darifenacin

oral

DRUG

imidafenacin

oral

DRUG

tolterodine

oral

DRUG

oxybutynin

oral

DRUG

trospium

oral

DRUG

fesoterodine

oral

DEVICE

propiverine

oral

Trial Locations (15)

Unknown

Site KR410008, Daejeon

Site KR410009, Incheon

Site KR410005, Kangam

Site KR410001, Seoul

Site KR410002, Seoul

Site KR410003, Seoul

Site KR410006, Seoul

Site KR410007, Seoul

Site KR410004, Suwon

Site TW158001, Hualien City

Site TW158003, Kaohsiung City

Site TW158006, Kaohsiung City

Site TW158002, Taichung

Site TW158004, Taipei

Site TW158005, Taoyuan

All Listed Sponsors

lead

Astellas Pharma Singapore Pte. Ltd.

INDUSTRY

NCT03572231 - A Registry Study of Patients Initiating a Course of Drug Therapy for Overactive Bladder in Taiwan, Korea and China | Biotech Hunter | Biotech Hunter